Sunstone is a leader in the delivery of psychedelic-assisted therapy in the medical setting, focusing on the development and execution of clinical trials today, and moving towards clinical delivery when therapies are approved. We aim to reduce the emotional suffering of those affected by cancer and complex mental health challenges and disorders, and to make safe, effective psychedelic-assisted therapy an accessible reality for all who might benefit from it. Fundamental to our approach is the belief that health is not just the absence of illness but a state of emotional, social, and spiritual well-being. In the last 12 months, Sunstone has treated more patients with PAT (not including ketamine) within a clinical setting than any other organization in the world. Delivery of psychedelic therapies is complex, requiring significant capabilities and experience in logistics, infrastructure and training, as well as clinical care. Sunstone’s patient-centric approach is based on the cancer care model, with the team drawing on their deep experience in oncology to provide the operational excellence to deliver complex, multi-faceted care at scale. Sunstone also provides training and education in PAT, as well as focusing on all aspects of clinic design and delivery including digital platforms, cost modeling, and quality of care.